Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

MLA

Si Su, et al. “Indication and Adverse Event Profiles of Denosumab and Zoledronic Acid: Based on U.S. FDA Adverse Event Reporting System (FAERS).” Frontiers in Pharmacology, vol. 14, Nov. 2023. EBSCOhost, https://doi.org/10.3389/fphar.2023.1225919.

APA

Si Su, Liuqing Wu, Guibao Zhou, Lingling Peng, Huanzhe Zhao, Xiao Wang, & Kuan Li. (2023). Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS). Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1225919

Chicago

Si Su, Liuqing Wu, Guibao Zhou, Lingling Peng, Huanzhe Zhao, Xiao Wang, and Kuan Li. 2023. “Indication and Adverse Event Profiles of Denosumab and Zoledronic Acid: Based on U.S. FDA Adverse Event Reporting System (FAERS).” Frontiers in Pharmacology 14 (November). doi:10.3389/fphar.2023.1225919.